{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:05:23Z","timestamp":1790208323945,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005869","name":"University of Fribourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Overproduction of the intrinsic chromosomally-encoded AmpC \u03b2-lactamase is one of the main mechanisms responsible for broad-spectrum \u03b2-lactam resistance in <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. Our study aimed to evaluate the in-vitro activity of anti-pseudomonal \u03b2-lactam molecules associated with the recently-developed and commercially-available \u03b2-lactamase inhibitors, namely avibactam, relebactam and vaborbactam, against <jats:italic>P. aeruginosa<\/jats:italic> isolates overproducing their AmpC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>MIC values of ceftazidime, cefepime, meropenem, imipenem and ceftolozane with or without \u03b2-lactam inhibitor were determined for 50 AmpC-overproducing <jats:italic>P. aeruginosa<\/jats:italic> clinical isolates. MIC breakpoints for resistance were retained at 8\u00a0mg\/L for \u03b2-lactams and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations containing ceftazidime, cefepime and meropenem, while 4\u00a0mg\/L was used for those containing imipenem and ceftolozane. The concentration of all \u03b2-lactamases inhibitors was fixed at 4\u00a0mg\/L, except for vaborbactam (8\u00a0mg\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The rates of isolates not being resistant to ceftazidime, cefepime, meropenem, imipenem and ceftolozane were found at 12%, 22%, 34%, 8% and 74%, respectively. When combined with avibactam, those rates increased to 60%, 62%, 60%, 46%, and 80%, respectively. The highest rates were found with relebactam-based combinations, being 76%, 64%, 66%, 76% and 84%, respectively. By contrast, associations with vaborbactam did not lead to significantly increased \u201cnon-resistance\u201d rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results showed that all combinations including relebactam led to higher \u201cnon-resistance\u201d rates against AmpC-overproducing <jats:italic>P. aeruginosa<\/jats:italic> clinical isolates. The best activity was achieved by combining ceftolozane and relebactam, that might therefore be considered as an excellent clinical alternative against AmpC overproducers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10096-024-04965-x","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:05:31Z","timestamp":1732622731000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In-vitro activity of newly-developed \u03b2-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal \u03b2-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-5576","authenticated-orcid":false,"given":"Christophe","family":"Le Terrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7374-0788","authenticated-orcid":false,"given":"Ot\u00e1vio Hallal Ferreira","family":"Raro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin Mohamed","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1622","authenticated-orcid":false,"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-5286","authenticated-orcid":false,"given":"Laurent","family":"Poirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"4965_CR1","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.drup.2019.07.002","volume":"44","author":"J Botelho","year":"2019","unstructured":"Botelho J, Grosso F, Peixe L (2019) Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Updat 44:100640","journal-title":"Drug Resist Updat"},{"key":"4965_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-2994-3-32","volume":"3","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Raman G, Sulham K et al (2014) Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3:32","journal-title":"Antimicrob Resist Infect Control"},{"key":"4965_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/cid\/cix132","volume":"64","author":"AE Kizny Gordon","year":"2017","unstructured":"Kizny Gordon AE, Mathers AJ, Cheong EYL et al (2017) The hospital water environment as a reservoir for carbapenem-resistant organisms causing hospital-acquired infections-a systematic review of the literature. Clin Infect Dis 64:1435\u20131444","journal-title":"Clin Infect Dis"},{"key":"4965_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/2049-632X.12033","volume":"67","author":"SL Gellatly","year":"2013","unstructured":"Gellatly SL, Hancock RE (2013) Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159\u2013173","journal-title":"Pathog Dis"},{"key":"4965_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582\u2013610","journal-title":"Clin Microbiol Rev"},{"key":"4965_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","volume":"45","author":"A Potron","year":"2015","unstructured":"Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568\u2013585","journal-title":"Int J Antimicrob Agents"},{"key":"4965_CR7","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.01410-08","volume":"53","author":"JM Rodr\u00edguez-Mart\u00ednez","year":"2009","unstructured":"Rodr\u00edguez-Mart\u00ednez JM, Poirel L, Nordmann P (2009) Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:1766\u20131771","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR8","doi-asserted-by":"crossref","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","volume":"61","author":"E Del Barrio-Tofi\u00f1o","year":"2017","unstructured":"Del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Cabot G et al (2017) Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain. Antimicrob Agents Chemother 61:e01589\u2013e01517","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1469-0691.2006.01674.x","volume":"13","author":"VH Tam","year":"2007","unstructured":"Tam VH, Schilling AN, LaRocco MT et al (2007) Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 13:413\u2013418","journal-title":"Clin Microbiol Infect"},{"key":"4965_CR10","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1128\/AAC.01645-10","volume":"55","author":"G Cabot","year":"2011","unstructured":"Cabot G, Ocampo-Sosa AA, Tubau F et al (2011) Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906\u20131911","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR11","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","volume":"32","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32:e00031\u2013e00019","journal-title":"Clin Microbiol Rev"},{"key":"4965_CR12","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L (2020) New \u03b2-Lactam-\u03b2-Lactamase inhibitor combinations. Clin Microbiol Rev 34:e00115\u2013e00120","journal-title":"Clin Microbiol Rev"},{"key":"4965_CR13","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1128\/AAC.01404-13","volume":"57","author":"A Walkty","year":"2013","unstructured":"Walkty A, Karlowsky JA, Adam H et al (2013) In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 57:5707\u20135709","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jac\/dkaa430","volume":"76","author":"M Hern\u00e1ndez-Garc\u00eda","year":"2021","unstructured":"Hern\u00e1ndez-Garc\u00eda M, Garc\u00eda-Castillo M, Garc\u00eda-Fern\u00e1ndez S et al (2021) Distinct epidemiology and resistance mechanisms affecting ceftolozane\/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. J Antimicrob Chemother 76:370\u2013379","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54:969\u2013976","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","volume":"14","author":"K Coleman","year":"2011","unstructured":"Coleman K (2011) Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors. Curr Opin Microbiol 14:550\u2013555","journal-title":"Curr Opin Microbiol"},{"key":"4965_CR17","doi-asserted-by":"publisher","first-page":"e0033923","DOI":"10.1128\/aac.00339-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Freret C et al (2023) Impact of acquired broad spectrum \u03b2-lactamases on susceptibility to novel combinations made of \u03b2-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel \u03b2-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 67:e0033923","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR18","doi-asserted-by":"crossref","unstructured":"Le Terrier C, Mlynarcik P, Sadek M et al (2024) Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone \u03b2-lactamase inhibitors against broad-spectrum AmpC \u03b2-lactamases. Antimicrob Agents Chemother\u00a04:e0077524.","DOI":"10.1128\/aac.00775-24"},{"key":"4965_CR19","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1128\/AAC.00825-15","volume":"59","author":"M Berrazeg","year":"2015","unstructured":"Berrazeg M, Jeannot K, Ntsogo Engu\u00e9n\u00e9 VY et al (2015) Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother 59:6248\u20136255","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR20","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1128\/JCM.01597-12","volume":"50","author":"L Dortet","year":"2012","unstructured":"Dortet L, Poirel L, Nordmann P (2012) Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol 50:3773\u20133776","journal-title":"J Clin Microbiol"},{"key":"4965_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jgar.2019.10.014","volume":"21","author":"C Le Terrier","year":"2020","unstructured":"Le Terrier C, Masseron A, Uwaezuoke NS et al (2020) Wide spread of carbapenemase-producing bacterial isolates in a Nigerian environment. J Glob Antimicrob Resist 21:321\u2013323","journal-title":"J Glob Antimicrob Resist"},{"key":"4965_CR22","unstructured":"EUCAST (2024) Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0 https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_14.0_Breakpoint_Tables.pdf"},{"key":"4965_CR23","doi-asserted-by":"publisher","first-page":"1140515","DOI":"10.3389\/fmicb.2023.1140515","volume":"14","author":"L Meng","year":"2023","unstructured":"Meng L, Cao X, Li C et al (2023) Housekeeping gene stability in Pesudomonas Aeruginosa PAO1 under the pressure of commonly used antibiotics in molecular microbiology assays. Front Microbiol 14:1140515","journal-title":"Front Microbiol"},{"key":"4965_CR24","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1093\/jac\/dkx298","volume":"72","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Jamrozy D, Mushtaq S et al (2017) AmpC \u03b2-lactamase induction by avibactam and relebactam. J Antimicrob Chemother 72:3342\u20133348","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR25","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45","journal-title":"Nucleic Acids Res"},{"key":"4965_CR26","unstructured":"EUCAST (2024) MIC determination of non-fastidious and fastidious organisms. https:\/\/www.eucast.org\/ast_of_bacteria\/mic_determination"},{"key":"4965_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10096-023-04732-4","volume":"43","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier C, Freire S, Nordmann P et al (2024) Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility\/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Eur J Clin Microbiol Infect Dis 43:339\u2013354","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4965_CR28","unstructured":"Clinical and Laboratory Standards Institute (2023) Performance standards for antimicrobial susceptibility testing, 33rd ed. CLSI M100. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"4965_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/dkac360","volume":"78","author":"C Le Terrier","year":"2022","unstructured":"Le Terrier C, Nordmann P, Poirel L (2022) In vitro activity of aztreonam in combination with newly developed \u03b2-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-\u03b2-lactamases. J Antimicrob Chemother 78:101\u2013107","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR30","doi-asserted-by":"publisher","first-page":"e0044023","DOI":"10.1128\/aac.00440-23","volume":"67","author":"O Lomovskaya","year":"2023","unstructured":"Lomovskaya O, Castanheira M, Lindley J et al (2023) In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing enterobacterales. Antimicrob Agents Chemother 67:e0044023","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","volume":"19","author":"K Young","year":"2019","unstructured":"Young K, Painter RE, Raghoobar SL et al (2019) In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 19:150","journal-title":"BMC Microbiol"},{"key":"4965_CR32","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1128\/AAC.44.12.3322-3327.2000","volume":"44","author":"N Masuda","year":"2000","unstructured":"Masuda N, Sakagawa E, Ohya S et al (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3322\u20133327","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR33","doi-asserted-by":"publisher","first-page":"e02165","DOI":"10.1128\/AAC.02165-19","volume":"64","author":"PA Fraile-Ribot","year":"2020","unstructured":"Fraile-Ribot PA, Zamorano L, Orellana R et al (2020) Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants. Antimicrob Agents Chemother 64:e02165\u2013e02119","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR34","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","volume":"75","author":"MA Gomis-Font","year":"2020","unstructured":"Gomis-Font MA, Cabot G, S\u00e1nchez-Diener I et al (2020) In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa. J Antimicrob Chemother 75:2508\u20132515","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR35","first-page":"2286","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Meunier D, Hopkins KL et al (2013) Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286\u20132290","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jac\/dkx438","volume":"73","author":"DM Livermore","year":"2018","unstructured":"Livermore DM, Meunier D, Hopkins KL et al (2018) Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. J Antimicrob Chemother 73:648\u2013657","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ijantimicag.2015.07.004","volume":"46","author":"M Tato","year":"2015","unstructured":"Tato M, Garc\u00eda-Castillo M, Bofarull AM et al (2015) In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int J Antimicrob Agents 46:502\u2013510","journal-title":"Int J Antimicrob Agents"},{"key":"4965_CR38","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/AAC.00296-10","volume":"54","author":"B Moy\u00e1","year":"2010","unstructured":"Moy\u00e1 B, Zamorano L, Juan C et al (2010) Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:3933\u20133937","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR39","doi-asserted-by":"publisher","first-page":"e00084","DOI":"10.1128\/AAC.00084-21","volume":"65","author":"AM Rubio","year":"2021","unstructured":"Rubio AM, Kline EG, Jones CE et al (2021) In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment - emergent resistance to ceftolozane-tazobactam. Antimicrob Agents Chemother 65:e00084\u2013e00021","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X et al (2018) Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 73:658\u2013663","journal-title":"J Antimicrob Chemother"},{"key":"4965_CR41","doi-asserted-by":"publisher","first-page":"114835","DOI":"10.1016\/j.diagmicrobio.2019.05.007","volume":"96","author":"GG Stone","year":"2020","unstructured":"Stone GG, Smayevsky J, Kazmierczak K (2020) Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016. Diagn Microbiol Infect Dis 96:114835","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4965_CR42","doi-asserted-by":"publisher","first-page":"e0198521","DOI":"10.1128\/aac.01985-21","volume":"66","author":"LY Lin","year":"2022","unstructured":"Lin LY, Debabov D, Chang W et al (2022) Antimicrobial activity of ceftazidime-avibactam and comparators against pathogens harboring OXA-48 and AmpC alone or in combination with other \u03b2-lLactamases collected from phase 3 clinical trials and an international surveillance program. Antimicrob Agents Chemother 66:e0198521","journal-title":"Antimicrob Agents Chemother"},{"key":"4965_CR43","doi-asserted-by":"publisher","first-page":"106521","DOI":"10.1016\/j.ijantimicag.2022.106521","volume":"59","author":"SS Jean","year":"2022","unstructured":"Jean SS, Lu MC, Ho MW et al (2022) Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019. Int J Antimicrob Agents 59:106521","journal-title":"Int J Antimicrob Agents"},{"key":"4965_CR44","doi-asserted-by":"publisher","first-page":"106066","DOI":"10.1016\/j.ijantimicag.2020.106066","volume":"56","author":"M Iannaccone","year":"2020","unstructured":"Iannaccone M, Boattini M, Bianco G et al (2020) Meropenem\/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 56:106066","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04965-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:47:48Z","timestamp":1737557268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04965-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}